Advanced Medical Optics, Inc. v. Alcon Inc.

361 F. Supp. 2d 370, 2005 WL 705235
CourtDistrict Court, D. Delaware
DecidedMarch 28, 2005
DocketCIV.A.03-1095-KAJ
StatusPublished
Cited by3 cases

This text of 361 F. Supp. 2d 370 (Advanced Medical Optics, Inc. v. Alcon Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Advanced Medical Optics, Inc. v. Alcon Inc., 361 F. Supp. 2d 370, 2005 WL 705235 (D. Del. 2005).

Opinion

MEMORANDUM OPINION

JORDAN, District Judge.

I. INTRODUCTION

This is a patent infringement case. Presently before me are the parties’ requests for construction of the disputed claim language of U.S. Patent No. 5,700,-240 (issued Dec. 23, 1997) (the “ ’240 patent”) and U.S. Patent No. 6,059,765 (issued May 9, 2000) (the “ ’765 patent”), pursuant to Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed.Cir.1995) (en banc), aff’d, 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996). The plaintiff in this case is Advanced Medical Optics, Inc. (“AMO”). The defendants are Alcon Laboratories, Inc. and Alcon Manufacturing, Ltd. (collectively, “Alcon”). The parties have fully briefed and argued their positions. Jurisdiction is proper under 28 U.S.C. § 1338.

II. BACKGROUND

A. Procedural Background

AMO filed a complaint for patent infringement against Alcon Laboratories, Inc. on December 3, 2003. (Docket Item [“D.I.”] 1.) AMO subsequently filed an amended complaint adding Alcon Manufacturing, Ltd. on February 13, 2004. (D.I. *374 25.) Alcon filed an answer to AMO’s amended complaint on March 3, 2004 and asserted a counterclaim for a declaratory judgment that the ’240 and ’765 patents are “not infringed and/or are invalid.” (D.I. 34 at 8.) AMO filed a reply to Alcon’s counterclaim, denying that the patents at issue are either invalid or not infringed. (D.I. 40.) AMO and Alcon are scheduled to try this case before a jury beginning on April 25, 2005. (D.I. 32.)

B. The Disclosed Technology

The ’240 patent discloses an apparatus and method for performing certain aspects of a surgical technique to remove cataracts using phacoemulsification. (See ’765 patent, Abstact.) The ’765 patent discloses a fluid management system, specifically a fluid management apparatus and method for reducing expandable gas in the aspiration line of a fluid management system. {See ’240 patent, col. 2, 11. 26-27, col. 4, 11. 58-col. 6,11. 62.)

1. The State of the Art

A cataract is “an opacification of the lens of the eye that obstructs normal vision,” and is often accompanied by a hardening of the lens. (D.I. 151, Ex. 3A at A0048, Expert Report of Mr. George Eilers.) During cataract surgery, the diseased lens is removed and replaced with an artificial lens. (Id. at A0049.) The surgery generally consists of making an incision in the eye, removing the diseased lens, and inserting the implant. (Id.) Because of medical considerations, it is desirable to make the smallest incision possible, often smaller than the lens itself. (Id.) In order to extract the lens through such a small incision, various surgical techniques have been developed to reduce the lens to smaller pieces before removing it. (Id.) Phacoe-mulsification “has become the preferred technique” for accomplishing this task. (Id.) Phacoemulsification involves inserting a hollow needle into the incision in the eye and delivering high-level ultrasonic energy to the lens to break it into small pieces which can then be removed. (Id.) A vacuum is applied to the needle to aspirate, and thereby remove, the broken pieces of the lens. (Id.) During this procedure, irrigating fluid is also delivered to the eye through a sleeve that surrounds the inserted needle. (Id.) The irrigating fluid serves at least two functions: it replaces the fluid that is aspirated by the vacuum and it cools the eye by removing the heat generated by the ultrasonic energy. (Id.)

The surgical instrument commonly used in modern day phacoemulsification systems is a handpiece containing a tip (the aforesaid needle) that can be activated to vibrate at ultrasonic frequencies. (D.I. 138 at 1.) The handpiece is connected to a console that controls the various functions of the machine. (Id. at 2.) Connected to the handpiece are a tube for bringing the irrigating fluid to the surgical site, a second tube, which is connected to a pump that provides suction to perform the aspirating function, and a cable that connects the handpiece to the console containing the source of ultrasonic power. (Id.) “These systems have control units that include a variable speed peristaltic pump, a vacuum sensor, an adjustable source of ultrasonic power and a programmable microprocessor with operator-selected presets for controlling aspiration rate, vacuum and ultrasonic power levels.” (’240 patent, col. 1, 11. 51-56.)

To perform a phacoemulsification procedure, the surgeon would typically control the various components by depressing a foot pedal “to initiate the delivery of irrigation fluid, the aspiration of fluid, and the delivery of ultrasonic power.” (D.I. 151, Ex. 3A at A0049, Expert Report of Mr. George Eilers.) The surgeon could program the microprocessor by setting maximum ultrasonic power levels, to limit the *375 amount of power delivered to the surgical site. (Id.) The microprocessor could also “control the aspiration rate by controlling the speed of the peristaltic pump ... [and] limit the aspiration rate to a present flow rate.” (Id.)

During the procedure, the broken lens is drawn to the tip of the needle by the fluid flow. (Id. at A0050.) Occasionally, an occlusion or blockage of the opening of the needle can occur, reducing or stopping the flow of fluid. (Id.) A lens fragment or kink in the tubing may block the flow of fluid in the tubing connecting the handpiece to the vacuum pump. (Id.) In response to an occlusion, surgeons can either increase or decrease the ultrasonic power in an attempt to clear the blockage and resume the normal fluid flow. (Id.) Occlusions can be dangerous to the patient because, if the ultrasonic power is increased, the increased heat generated at the incision site may cause a corneal burn. (Id.) Further, if the pump continued to run, during an occluded state, the vacuum level in the aspiration line would increase and could lead to a sudden flow surge once the occlusion was cleared. (Id.) Thus, occlusions were considered by some surgeons to be problematic during phacoemulsification procedures. 1 (D.I. 138 at 2.)

2. The ’240 Patent

The ’240 patent discloses a method and apparatus for varying the ultrasonic power delivered to the surgical handpiece during a phacoemulsification procedure. (’240 patent, Abstract.) AMO has asserted claims 1, 3, 5, and 6 against Alcon in this litigation. (D.I. 25 at ¶ 12; D.I.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Smartflash LLC v. Apple Inc.
77 F. Supp. 3d 535 (E.D. Texas, 2014)
Michilin Prosperity Co. v. Fellowes Manufacturing Co.
422 F. Supp. 2d 86 (District of Columbia, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
361 F. Supp. 2d 370, 2005 WL 705235, Counsel Stack Legal Research, https://law.counselstack.com/opinion/advanced-medical-optics-inc-v-alcon-inc-ded-2005.